Index

Note: Page numbers of article titles are in **boldface** type.

A
Abatacept, infectious complications associated with, 294–295
Adalimumab, infectious complications associated with, 288–291
Adenovirus, 341–345
  clinical aspects of, 343–344
  immunologic aspects of, 341–343
  immunotherapy for, after transplantation, 523
  in transplant and oncology patients, 401–402
  therapeutic aspects of, 344–345
  virological aspects of, 341
Alefacept, infectious complications associated with, 296
Alemtuzumab, infectious complications associated with, 292–293
Ameba(s), free-living, in solid-organ transplant recipients, 470–471
Amebiasis, in solid-organ transplant recipients, 475
American trypanosomiasis, in solid-organ transplant recipients, 468–470
Anakinra, infectious complications associated with, 291–292
Anti–interleukin-1 (IL-1), infectious complications associated with, 291–292
Antilymphocyte therapies, infections related to, 277–278
Anti–tumor necrosis factor-α (TNF-α), infectious complications associated with, 288–291
Antiviral agents, in prevention of CMV in HSCT recipients, 323–325
Antiviral drug resistance, **413–437**. See also specific diseases.
  CMV, 417–421
    future directions in, 425
  HBV, 421–425
  herpesviruses, 413–415
  HSV, 415–416
  VZV, 416–417
Aspergillus spp., 440–441
  management of, 447–448

B
Babesiosis, in solid-organ transplant recipients, 467–468
Basiliximab, infectious complications associated with, 294
Belatacept, infectious complications associated with, 2942–95
Biologic agents, immunomodulating, infectious complications associated with, **285–306**. See also Immunomodulating biologic agents, infectious complications associated with.
B-lymphocyte depletion, rituximab and, 286–288

doi:10.1016/S0891-5520(10)00024-3 id.theclinics.com
0891-5520/10/$ – see front matter © 2010 Elsevier Inc. All rights reserved.
Bocavirus, in transplant and oncology patients, 403–404
Bone marrow transplantation, 257–272. See also Hematopoietic stem cell transplantation (HSCT).

C

Candida spp., 441
management of, 448–450
Certolizumab pegol, infectious complications associated with, 288–291
Chagas disease, assays for targeted use in, 505–506
Children, transplantation in
  hematopoietic, described, 311–314
  infections associated with, 307–318. See also Infection(s), in pediatric transplant recipients.
  prevalence of, 307
  solid-organ, described, 307–311
CMV. See Cytomegalovirus (CMV).
Coccidioides immitis, assays for targeted use in, 507
Community-acquired infections, transplantation and, 276
Coronaviruses (CoV), in transplant and oncology patients, 401
CoV. See Coronaviruses (CoV).
Cryptococcosis, management of, 451
Cryptococcus, 442–443
Cryptosporidiosis, in solid-organ transplant recipients, 472–474
Cyclosporiasis, in solid-organ transplant recipients, 474–475
Cytomegalovirus (CMV), 348–352
  after HSCT, 267
  antiviral drug resistance in, 417–421
  clinical implications of, 419–421
  epidemiology of, 417–418
  management of, 419–421
  mechanism of, 418–419
  clinical aspects of, 349
  described, 319–320
  immunotherapy for, after transplantation, 519–521
  in HSCT recipients, 319–337
  allogeneic, risk factors for, 321–322
  antiviral resistance to, 326
  autologous, risk factors for, 322–323
  clinical manifestations of, 321
  diagnostic methods, 320–321
  management of, 326–327
  prevention of, 323–326
  antiviral agents in, 323–325
  in special populations, 325–326
  risk factors for, 321–323
  in kidney transplantation, 349–352
  virological aspects of, 348

D

Daclizumab, infectious complications associated with, 294
Diarrhea, after HSCT, 266–267
EBV. See Epstein-Barr virus (EBV).
Echinococcosis, in solid-organ transplant recipients, 479–481
Efalizumab, infectious complications associated with, 295–296
Endemic fungi, 443
Epstein-Barr virus (EBV), in transplant recipients, 377–378
immunotherapy for, 521–523
Etanercept, infectious complications associated with, 288–291
Fever
neutropenic, after HSCT, 262–263
nonneutropenic, after HSCT, 262
Filariasis, in solid-organ transplant recipients, 481
Free-living amebas, in solid-organ transplant recipients, 470–471
Fungal infections, invasive, in transplant and oncology patients, 439–459. See also Invasive fungal infections (IFIs), in transplant and oncology patients.
Fungus(i), endemic, 443
Gemtuzumab ozogamicin, infectious complications associated with, 296
Golimumab, infectious complications associated with, 288–291
HCMV vaccines, after transplantation, 516–517
Helminths, in solid-organ transplant recipients, 475–481. See also specific disorders.
Hematopoietic stem cell transplantation (HSCT), 257–272
CMV in recipients of, 267, 319–337. See also Cytomegalovirus (CMV), in HSCT recipients.
described, 257–259
diarrhea after, 266–267
hepatitis after, 268
IFIs in, timing of, 443–445
immunity after, 259–262
in children, infections in, 311–314
infectious syndromes after, 262–269
prevention of, 269
treatment of, 269
neutropenic fever after, 262–263
nonneutropenic fever after, 262
pneumonia after, 262–266
pulmonary infiltrates after, 262–266
rash after, 268–269
restoration of host defenses after, 259–262
supportive care after, 259
types of, 258
Hepatitis
after HSCT, 268
B antiviral drug resistance in, 421–425
clinical implications of, 424–425
Hepatitis (continued)
  epidemiology of, 422
  management of, 424–425
  mechanism of, 421, 423–424
  susceptibility evaluation, 421–422
  screening tests for, in transplantation-transmitted infections evaluation, 501, 502, 504
  C, screening tests for, in transplantation-transmitted infections evaluation, 501–503
Herpes simplex virus (HSV)
  antiviral drug resistance in, 415–416
    clinical implications of, 416
    epidemiology of, 415
    management of, 416
    mechanisms of, 415–416
  in transplant recipients
    type 1, 373–375
    type 2, 373–375
Herpesvirus(es)
  antiviral agents for
    in vitro susceptibility testing, 414–415
    mechanism of action of, 413–414
  antiviral drug resistance in, 413–415
  in transplant recipients. See also specific types, e.g., Herpes simplex virus (HSV), type 1.
    EBV, 377–378
    HHV, 378–381
    HSV-1, 373–375
    HSV-2, 373–375
    VZV, 375–376
    type 6, 352–354. See also Human herpesvirus (HHV), type 6.
    type 7, 352–354. See also Human herpesvirus (HHV), type 7.
HHV. See Human herpesvirus (HHV).
Histoplasma capsulatum, assays for targeted use in, 507
HIV infection, screening tests for, in transplantation-transmitted infections evaluation, 501, 503
Host defenses, restoration of, HSCT and, 259–262
HPV vaccines, after transplantation, 518
HSCT. See Hematopoietic stem cell transplantation (HSCT).
HSV. See Herpes simplex virus (HSV).
HTLV-1/-2, screening tests for, in transplantation-transmitted infections evaluation, 504
Human cytomegalovirus (HCMV) vaccines, after transplantation, 516–517
Human herpesvirus (HHV)
  type 6, 352–354
    clinical aspects of, 353
    in kidney transplantation, 353–354
    in transplant recipients, 378–379
    virological aspects of, 352–353
  type 7, 352–354
    clinical aspects of, 353
    in kidney transplantation, 353–354
    in transplant recipients, 378–379
    virological aspects of, 352–353
  type 8, in transplant recipients, 380–381
Human metapneumovirus, in transplant and oncology patients, 400–401
Human papillomavirus (HPV) vaccines, 518
Hyaline hyphomycetes, 441
Hyphomycetes, hyaline, 441

I

IFIs. See *Invasive fungal infections (IFIs).*
Immunity, restoration of, HSCT and, 259–262
Immunomodulating biologic agents, infectious complications associated with, 285–306. See also specific agents.
alefacept, 296
alemtuzumab, 292–293
anti–IL-1 therapies, 291–292
anti-TNF–α, 288–291
blocking activated T-lymphocytic proliferation, 294
B-lymphocyte depletion, 286–288
described, 285–286
prolonged neutropenia, 296
selective T-cell costimulation blockade, 294–295
therapies interfering with T-lymphocyte migration, 295–296
Immunosuppression, net state of, 276–278
Immunotherapy
adoptive
after HSCT, CMV, 326–327
after transplantation, 519–523
adenovirus, 523
CMV, 519–521
EBV, 521–523
after transplantation, 519–523
described, 515
Infection(s). See specific types.
complications of, immunomodulating biologic agents and, 285–306. See also *Immunomodulating biologic agents, infectious complications associated with.*
in pediatric transplant recipients, 307–318. See also Children, transplantation in.
HSCT, 311–314
late post-transplant period, 313
postengraftment period, 312–313
pre-engraftment period, 312
pretransplant period, 311–312
prevention, 313–314
solid organ transplantation, 308–311
intraoperative factors, 309–310
post-transplant risk factors, 310
pretransplant risk factors, 308–309
prevention, 310–311
transplantation-related, 273–283
antilymphocyte therapies and, 277–278
community-acquired, 276
donor-derived, 275
epidemiologic exposures and, 275–276
future directions in, 279
Infection(s) (continued)

- general concepts, 273–274
- nosocomial, 276
- recipient-derived, 275–276
- risk factors for, 274–275
- time line of, 278–279
- viral, indirect effects of, 276–277

Transplantation-transmitted, 497–514

- current screening requirements and limitations, 499–504
  - HBV screening, 501, 502, 504
  - HCV screening, 501–503
  - HIV screening, 501, 503
  - HTLV-1/-2 screening, 504
- in organ donor, challenges of, 504–505
- described, 497
- donor-derived, management of, 508–509
- epidemiology of, 497–499
- organ donor screening, assays for targeted use in, 505–507
- research related to, 509
- risk factors for, management of, 507–508
- significance of, 497–499

Infliximab, infectious complications associated with, 288–291

Influenza, in transplant and oncology patients, 397–399

Intestinal protozoas, in solid-organ transplant recipients, 471–475. See also specific disorders.

Invasive fungal infections (IFIs), in transplant and oncology patients, 439–459

- Aspergillus spp., 440–441
- Candida spp., 441
- cryptococcus, 442–443
- endemic fungi, 443
- epidemiology of, 439–440
- hyaline hyphomycetes, 441
- management of, 447–452
  - Aspergillus spp., 447–448
  - Candida spp., 448–450
  - cryptococcosis, 451
  - molds, 450
  - Pneumocystis jiroveci, 442, 450–451
  - surgical, 451–452
  - zygomycetes, 441–442, 450
- risk factors for, 446–447
- timing of, 443–446
- types of, 440–443

K

KI polyomavirus, in transplant and oncology patients, 404

Kidney graft function

- kidney transplantation in, 344–345. See also Kidney transplantation.
- long-term, viral impact on, 339–371
  - adenovirus, 341–345
  - CMV, 348–352
human herpesvirus-6 and -7, 352–354
parvovirus B19, 354–356
polyomavirus BK and JC, 345–348

Kidney transplantation
adenovirus in, 344
CMV in, 349–352
parvovirus B19 in, 354–356
polyomaviruses BK and JC in, 347–348

Leishmaniasis, in solid-organ transplant recipients, 463–465
Lung transplant recipients, respiratory viral infections in, clinical significance of, 404–405

Malaria, in solid-organ transplant recipients, 465–467
Microsporidiosis, in solid-organ transplant recipients, 471–472
Mold(s), management of, 450
Mycobacterium tuberculosis, assays for targeted use in, 506

Natalizumab, infectious complications associated with, 295–296
Neutropenia, prolonged, infectious complications associated with, 296
Neutropenic fever, after HSCT, 262–263
Nonneutropenic fever, after HSCT, 262
Nosocomial infections, transplantations and, 276

Parainfluenza, in transplant and oncology patients, 399–400
Parasitic infections, in solid-organ transplant recipients, 461–495
amebiasis, 475
American trypanosomiasis, 468–470
babesiosis, 467–468
cryptosporidiosis, 472–474
cyclosporiasis, 474–475
described, 461
echinococcosis, 479–481
filariasis, 481
free-living amebas, 470–471
helminths, 475–481
intestinal protozoas, 471–475. See also specific disorders.
leishmaniasis, 463–465
malaria, 465–467
microsporidiosis, 471–472
nonintestinal protozoa, 461–471. See also specific disorders.
schistosomiasis, 477–479
strongyloidiasis, 475–477
toxoplasmosis, 461–463
Parovirus B19, 354–356
immune response in, 354
in kidney transplantation, 354–356
Parvovirus B19 (continued)
in transplant and oncology patients, 403
replication and, 354
treatment of, 356
virological aspects of, 354

Pneumocystis jiroveci, 442
management of, 450–451

Pneumonia(s), after HSCT, 262–266

Polyomavirus(es)
BK and JC, 345–348
clinical aspects of, 347
immunologic aspects of, 346–347
in kidney transplantation, 347–348
therapeutic aspects of, 348
virological aspects of, 345–346

KI and WU, in transplant and oncology patients, 404

Protozoa(s)
intestinal, in solid-organ transplant recipients, 471–475. See also specific disorders.
nonintestinal, parasitic infections due to, in solid-organ transplant recipients, 461–471.
See also specific disorders.

Pulmonary infiltrates, after HSCT, 262–266

R

Rash(es), after HSCT, 268–269

Respiratory syncytial virus (RSV), in transplant and oncology patients, 400

Respiratory viral infections, in transplant and oncology patients, 395–412
adenovirus, 401–402
bocavirus, 403–404
clinical presentation of, 396
complications of, 396
CoV, 401
described, 395
epidemiology of, 395–396
human metapneumovirus, 400–401
infection control in, 405
influenza, 397–399
KI polyomavirus, 404
laboratory diagnosis of, 397–404
lung transplant recipients, clinical significance of, 404–405
parainfluenza, 399–400
parvovirus B19, 403
pathogenesis of, 395–396
rhinovirus, 402–403
RSV, 400
SARS, 401
transmission of, 395–396
WU polyomavirus, 404

Rhinovirus, in transplant and oncology patients, 402–403
Rilonacept, infectious complications associated with, 291–292
Rituximab, infectious complications associated with, 286–288

RSV. See Respiratory syncytial virus (RSV).
SARS, in transplant and oncology patients, 401
Schistosomiasis, in solid-organ transplant recipients, 477–479
Solid-organ transplant recipients
  infection in, risk factors for, 274–275
  management of, organs from increased risk donors and, 507–508
  parasitic infections in, 461–495. See also Parasitic infections, in solid-organ transplant recipients.
Solid-organ transplantation, IFIs in, timing of, 445–446
Strongyloides stercoralis, assays for targeted use in, 506–507
Strongyloidiasis, in solid-organ transplant recipients, 475–477

T
T-cell costimulation blockers, infectious complications associated with, 294–295
T-lymphocyte(s)
  migration of, therapies interfering with, infectious complications associated with, 295–296
  proliferations of, blocking activated, infectious complications associated with, 294
  TNF-α. See Tumor necrosis factor-α (TNF-α).
Toxoplasma gondii, assays for targeted use in, 507
Toxoplasmosis, in solid-organ transplant recipients, 461–463
TRANSNET. See Transplant Associated Infections Surveillance Program (TRANSNET).
Transplant Associated Infections Surveillance Program (TRANSNET), 439
Transplantation(s). See also specific types.
  bone marrow, 257–272. See also Hematopoietic stem cell transplantation (HSCT).
  hematopoietic stem cell, 257–272. See also Hematopoietic stem cell transplantation (HSCT).
  IFIs in patients with, 439–459
  immunotherapy after, 519–523. See also Immunotherapy.
  in children, infections associated with, 307–318. See also Infection(s), in pediatric transplant recipients.
  infections related to, 273–283. See also Infection(s), transplantation-related.
  infections transmitted by, 497–514. See also Infection(s), transplantation-transmitted.
  kidney. See Kidney transplantation.
  organ donors in, increased risk, management of recipients of organs from, 507–508
  respiratory viral infections in recipients of, 395–412. See also Respiratory viral infections, in transplant and oncology patients.
  solid-organ. See Solid-organ transplant recipients; Solid-organ transplantation.
  vaccination after, 515–519. See also Vaccination, after transplantation.
Trypanosomiasis, American, in solid-organ transplant recipients, 468–470

V
Vaccination, after transplantation, 515–519
  described, 515
  HCMV vaccines, 516–517
  HPV vaccines, 518
  VZV vaccine, 518–519
Vaccine(s), after transplantation
  HCMV, 516–517
  HPV, 518
Vaccine(s) (continued)

VZV, 518–519

Varicella zoster virus (VZV)
- antiviral drug resistance in, 416–417
- clinical implications of, 417
- epidemiology of, 416–417
- management of, 417
- mechanisms of, 417
- in transplant recipients, 375–376

Varicella zoster virus (VZV) vaccine, after transplantation, 518–519

Viral infections, transplantations and, indirect effects of, 276–277

VZV. See Varicella zoster virus (VZV).

W

West Nile virus, assays for targeted use in, 506

WU polyomavirus, in transplant and oncology patients, 404

Z

Zygomycetes, 441–442
- management of, 450